Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback